COVID-19 and emerging viral infections: The case for interferon lambda

Ludmila Prokunina-Olsson, Noémie Alphonse, Ruth E. Dickenson, Joan E. Durbin, Jeffrey S. Glenn, Rune Hartmann, Sergei V. Kotenko, Helen M. Lazear, Thomas R. O’Brien, Charlotte Odendall, Olusegun O. Onabajo, Helen Piontkivska, Deanna M. Santer, Nancy C. Reich, Andreas Wack, Ivan Zanoni

Research output: Contribution to journalReview articlepeer-review

155 Scopus citations

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.

Original languageEnglish (US)
Article numbere20200653
JournalJournal of Experimental Medicine
Volume217
Issue number5
DOIs
StatePublished - May 4 2020

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'COVID-19 and emerging viral infections: The case for interferon lambda'. Together they form a unique fingerprint.

Cite this